FDA accepts Neovasc’s Reducer application; shares up
Nano cap Neovasc (NASDAQ:NVCN) is up 26% premarket on light volume in reaction to its announcement that the FDA has accepted for review its marketing application for its Reducer device for the treatment of refractory angina.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.